Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Three factors to unlock the value of AI for life sciences

Posted on May 1st, 2019 by

Pharma R&D

Artificial Intelligence (AI) has been at the top of many boardroom agendas for the last several years, as execs try to integrate the technology. Recent RELX research found that, across all industries, 88 percent of senior executives believe AI will help their businesses be more competitive. In the life sciences, AI has the potential to scale the benefits of precision medicine or automated disease prediction to more patients across the world, and could generate more than $150 billion in savings for the healthcare industry by 2025. 

(more…)

Elsevier is recognized as ‘Best of Show Award Finalist’ and ‘Innovative Practices Finalist” at Bio-IT World Conference & Expo 2019

Posted on April 29th, 2019 by

Pharma R&D

Elsevier held a prominent place at last weeks Bio-IT World conference, recognized as a finalist for both ‘Best of Show’ as well as ‘People’s Choice. Highlighted was Elsevier’s Entellect, a new platform for integrated data management in pharmaceutical and life sciences industries.

(more…)

The Cancer-Killing Nanorobots are Coming

Posted on April 26th, 2019 by

Pharma R&D

In recent years, robotics, AI, and Machine Intelligence have been at the forefront of the symbiotic need for humans and our own AI technology to work together. Last year, ground breaking research by molecular chemists at Arizona State University has taken cancer research and treatment to a new level. They are in the process of developing an “origami-inspired” system that can identify the tumor, attack, and deploy a mechanism to suffocate the tumor. Innovation is everywhere in this field, and this one is truly amazing.

(more…)

On World Malaria Day, Assessing Progress in the Fight Against a Persistent Disease

Posted on April 25th, 2019 by

Pharma R&D

Today marks the WHO’s worldwide recognition of those affected by malaria and the widespread global effort to develop a cure. The Elsevier Professional Services team exemplifies this effort with the creation of a database covering interactions and functions of P. faciparum proteins. This is the deadliest of the Plasmodium species that cause malaria in human beings.

(more…)

Data Science Helps Assess the Safety of “Inactive” Ingredients in Drugs

Posted on April 23rd, 2019 by

Pharma R&D

Elsevier’s Maria Shkrob’s study takes an microscopic lens to the topic of how data mapping and analytics can exposure the “under the radar” effects and potential dangers of inactive ingredients in drugs.

(more…)

Machine Learning Is Accelerating the Pace of Drug Development, But Good Data is Key

Posted on April 19th, 2019 by

Pharma R&D

Artificial Intelligence, Machine Learning and Deep Learning are on the tip of everyone’s tongues when it comes to acceleration of the pace of discovery The Pharma R&D market is a perfect exemplification of this phenomenon. Medical advancements enabled by such technologies have proven to significantly accelerate discovery processes, saving valuable time and money required for the development of life changing solutions. That being said, there is the reality that human beings with a passion and talent for feeding such mechanisms still and likely always will provide invaluable inputs. In short, we are not to be replaced by these advancements; rather the changes are indicative of a new era of advancement defined by “partnerships” between humans and machines.

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 67


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.